Dr Gavin Stringfellow

Dr Gavin Stringfellow of Visionary Eye Specialists. Searching for an Ophthalmologist in Sydney? Gavin is highly regarded and professional.
Dr Gavin Stringfellow

Ophthalmic Surgeon

MBBS (Honours) FRANZCO


Dr Gavin Stringfellow brings a wide range of experience to his role at Visionary Eye Specialists. After completing his medical training at Sydney University and his specialty ophthalmology training at Prince of Wales Hospital, he spent an additional year at Moorfields Eye Hospital in London with a particular focus on cataract surgery.


While his main interests are in cataract surgery and glaucoma, he also enjoys the daily variety of general ophthalmology with the opportunity to treat people of all age groups with many different eye conditions including pterygium, uveitis, macula degeneration and other retinal disease as well as neuro-ophthalmology.


Dr Stringfellow has a passion for rural and indigenous health, and has been providing eye care to the remote outback communities of Bourke and Broken Hill for more than 20 years. Working with the Fred Hollows Foundation he has also performed volunteer eye surgery in Alice Springs.


Dr Stringfellow consults at both Hurstville and Miranda, and operates at Kogarah Private Hospital and Ramsay Surgical Centre Miranda.



Cataract surgery

  • Routine and complex cataract surgery
  • For suitable patients, options of premium intraocular lenses to reduce dependency on glasses after surgery
  • Surgery under local anaesthetic with sedation, for a comfortable experience


Pterygium surgery

  • Pterygium excision and conjunctival grafting
  • Surgery under local anaesthetic with sedation, for a comfortable experience


Comprehensive ophthalmology, including the management of:

  • Glaucoma
  • Macular degeneration
  • Diabetic eye disease
  • Uveitis and
  • Other common eye conditions

 

Current Hospital Appointments

Public Hospitals

Dr Stringfellow is part of the Outback Eye Service (OES) which is a program affiliated with Prince of Wales Hospital, Sydney and the Royal Flying Doctor Service (RFDS), providing ophthalmic care to the remote communities of Far West NSW:

  • Broken Hill Hospital
  • Bourke Hospital


Private Hospitals

  • Visiting Specialist Kogarah Private Hospital
  • Visiting Specialist Ramsay Surgical Centre Miranda


Current Private Practice Appointment

  • Director, Visionary Eye Specialists, Hurstville and Miranda

 

Qualifications and training

Post-graduate

  • Fellow of the Royal Australian and New Zealand College of Ophthalmologists (2003)


Undergraduate

  • Bachelor of Medicine (Honours) University of Sydney (1992)
  • Bachelor of Surgery (Honours) University of Sydney (1992)

 

Accredited Ophthalmology Training (1999-2003)

  • 2003 Cataract and Primary Care Fellowship, Moorfields Eye Hospital, London UK.
  • Routine and complex cataract surgery
  • Comprehensive ophthalmology and eye emergencies

 

Accredited registrar, Prince of Wales Hospital, Sydney (1999-2002)

  • Cataract surgery
  • Pterygium surgery
  • Oculoplastic surgery
  • Glaucoma
  • Retina
  • Cornea
  • Uveitis
  • Neuro-ophthalmology
  • Paediatric ophthalmology
  • General ophthalmology
  • Rural and remote ophthalmology

 

Pre-accredited Ophthalmology Training (1993-1998)

  •  1998 Ophthalmic surgical and clinical assistant, MetWest Eye Centre, Sydney.
  • 1997 Resident Medical Officer, St Vincents Private Hospital, Sydney
  • 1995-1996 Resident Medical Officer (Ophthalmology)
  • Whipps Cross Hospital, London UK
  • Central Middlesex Hospital, London UK
  • Royal Free Hospital, London UK
  •  1994 Resident Medical Officer, Concord Hospital
  •  1993 Intern, Westmead Hospital

 

Conferences and Scientific Meetings

  • 2020 Zeiss Advanced Biometry Webinar Series
  • 2020 RANZCO Webinar Series
  • 2019 RANZCO Congress (Sydney)
  • 2018 Australian Society of Cataract and Refractive Surgeons (Noosa)
  • 2018 World Ophthalmology Congress (Barcelona)
  • 2018 Ophthalmology Updates (Sydney)
  • 2017 Ophthalmology Updates (Sydney)
  • 2016 RANZCO Congress (Melbourne)
  • 2016 Ophthalmology Updates (Sydney)
  • 2015 Australian Society of Cataract and Refractive Surgeons (Noosa)
  • 2014 RANZCO Congress (Brisbane)
  • 2012 RANZCO Congress (Melbourne)
  • 2011 RANZCO Congress (Canberra)
  • 2010 European Society of Cataract and Refractive Surgeons (Paris)
  • 2009 RANZCO Congress (Brisbane)
  • 2008 American Society of Cataract and Refractive Surgeons (Chicago)
  • 2008 COSSOM POWH Ophthalmology Alumni Meeting
  • 2007 Australian Society of Cataract and Refractive Surgeons (Kingscliff)
  • 2006 RANZCO NSW Branch meeting (Newcastle)
  • 2006 COSSOM POWH Ophthalmology Alumni Meeting
  • 2005 European Society of Cataract and Refractive Surgeons (Lisbon)
  • 2004 RANZCO Congress (Melbourne)
  • 2004 COSSOM POWH Ophthalmology Alumni Meeting
  • 2004 RANZCO NSW Branch meeting (Leura)
  • 2003 American Society of Cataract and Refractive Surgeons (San Francisco)
  • 2003 UK and Ireland Society of Cataract and Refractive Surgeons (Chester)
  • 2002 World Ophthalmology Congress (Sydney)
  • 2001 RANZCO NSW Branch meeting (Sydney)


Indigenous and International Development (charity) work

  • 2012 Alice Springs intensive eye surgery “blitz” (Fred Hollows Foundation)
  • 2010 Alice Springs intensive eye surgery “blitz” (Fred Hollows Foundation)
  • 2006 Myanmar
  • 2001 Papua New Guinea

 

Publications

  • Stringfellow GJ, Francis IC. “Images in Clinical Medicine: Appearance of Intraocular Silicone Oil on Computed Tomography”. N Engl J Med. 2003; 348(12): 1122.
  • Stringfellow GJ, Francis IC, Coroneo MT, Walker J. “Case Report – Orbital Dirofilariasis” Clin Experiment Ophthalmol 2002; 30(5): 378-80.


CLINICAL TRIAL EXPERIENCE


Sub Investigator for International multicenter Randomised Clinical Trials:

 

Wet AMD

  • Bayer 20968 –Pulsar - Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration (2020-ongoing)
  •  Novartis Research and Development - CRTH258B2303- Talon -A 64-week, two-arm, randomized, double-masked, multi-center, phase 3b study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration (2019 ongoing)
  • Chengdu Kanghong Biotechnology Co., Ltd - KHB-1801- Phase 3, A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Agerelated Macular Degeneration.(PANDA) 2018-ongoing
  • Roche Products Pty Limited (Roche) GR40844 - Phase 3, Multi-Center, randomized, double-masked, active comparator controlled study to evaluate RO6867461 in patients with neovascular age-related macular degeneration (LUCERNE) (2019-ongoing)


Dry AMD

  • Apellis – A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (OAKS) (2019 – ongoing)
  • ISIS 696844-CS5 - Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) (IONIS) (2019-ongoing)
  • ISEE2008 A Phase 3 Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial To Assess The Safety And Efficacy Of Intravitreal Administration Of Zimura™ (Complement C5 Inhibitor) In Patients With Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration ( Oct 2020-ongoing)

 

Diabetes – DME

  • Novartis Pharmaceuticals Australia Pty Limited - Kestrel A Two-Year, Three-Arm, Randomized, Double Masked, Multicenter, Phase 3 Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KESTREL) (2018-ongoing)

 

RVO

  • Novartis Research and Development - CRTH258C2302 An Eighteen-Month, Two-Arm, Randomized, Double- Masked, Multicenter, Phase 3 Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion 
    (RAVEN) (2019-ongoing)

 

Completed Trials

  •  Opthea Limited - OPT-302-1003 - Phase 1b/2a study of OPT-302 in combination with aflibercept for persistent central-involved diabetic macular edema (OPTHEA) (2018-ongoing)


  • Bayer AG - BAY86-5321/17514 -A multi-center, single-arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion (Centera) (2017-2020)


  • Roche Pharmaceuticals: CHROMA Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety Of Lampalizumab Administered Intravitreal to Patients With Geographic Atrophy Secondary To AgeRelated Macular Degeneration


  • Roche Pharmaceuticals: OMASPECT Protocol GX30191 – Dec 2016 – 2017            A Multicentre, open-label extension study to evaluate the long-term safety and tolerability of Lampalizumab in patients with geographic atrophy secondary to age-related macular degeneration who have completed a Roche-sponsored study. 


  • Novartis Pharmaceuticals: Fluid study - Nov 2013 - 2017. A Phase IV, randomised, controlled study investigating the efficacy and safety of ranibizumab“inject and extend” using an intensive retinal fluid retreatment regimen compared to a relaxed retinal fluid retreatment regimen in patients with wet age related macular degeneration (AMD).


  • Ophthotech Pharmaceuticals; Eclipse study Dec 2013-201. A phase 3 Randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous ADMINISTRATION of FovistaTM (anti PDGF-b pegylated aptamer) administered in combination with Lucentis® COMPARED TO LUCENTIS® MONOTHERAPY in subjects with subfoveal neovascular age-related macular degeneration


  •  Novartis Pharmaceuticals: BRIGHTER STUDY 2012-2016. Study Title: A 24-month, phase IIIb, open-label, randomized, active-controlled, 3 arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5 mg ranibizumab intravitreal injections applied as monotherapy or with adjunctive laser photocoagulation in comparison to laser photocoagulation in patients with visual impairment due to Macular edema secondary to branch retinal vein occlusion (BRVO)



  •  Novartis Pharmaceuticals; CRYSTAL STUDY 2012-2014. Study Title: A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5mg ranibizumab intravitreal injections applied as monotherapy in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO)

 

  • Bayer Schering Pharmaceuticals VIVID VEGF Trap-Eye in DME 2011-2015. A randomized, double-masked, active-controlled phase 3 study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema

 

  • Bayer Schering Pharmaceuticals: Galilieo VEGF-Trap for CRVO  2009-2011. A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO)

 

  • Bayer Schering Pharmaceuticals: VIEW 2 VEGF-Trap for AMD 2008-2011. A randomized, double masked, active controlled, phase 3 study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap-Eye in subjects with neovascular age-related macular degeneration (AMD)
Share by: